Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMGN 289

Drug Profile

IMGN 289

Alternative Names: IMGN-289; R= J-2898-A

Latest Information Update: 12 Jun 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 24 Apr 2015 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 01 Apr 2015 ImmunoGen terminates a phase I trial in Solid tumours (Late-stage disease; Second-line therapy or greater) in USA (IV) (NCT01963715)
  • 09 Oct 2013 Phase-I clinical trials in Solid tumours (late-stage disease, second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top